9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Nanomedicine: Introduction and Overview. Clinical and laboratory Diagnosis of Autoimmune Diseases Invited speaker, 2011 World Allergy Congress, December, 2011, Cancun, Mexico December, 2011
2. Translating Nanotechnology into Therapeutics Keynote speaker, 2011 Annual Biomedical Engineering Faculty and Graduate Student Retreat, University of Michigan, September 2011, Brighton MI September, 2011
3. Welcome/Introductory Comments. Vice Chair, Cancer Nanotechnology, Gordon Research Conference, Colby College, July 2011, Waterville ME July, 2011
4. Nanotechnology for Cancer Approaches in the Clinic Plenary speaker, 7th International Dendrimer Symposium (IDS:7), NIST Campus, June 2011, Gaithersburg June, 2011
5. The development of dendrimer platforms for targeted drug delivery via combinatorial copper-free click chemistry. Poster, Department of Internal Medicine 19th Annual Research Day, University of Michigan, Ann Arbor MI May 20, 2011 May, 2011
6. Nanoemulsion (NE) intranasal adjuvant facilitates uptake of antigen loaded epithelial cells (EC) by dendritic cells (DC). 14th Annual Conference on Vaccine Research, NFID, Vaccine Adjuvants session, Baltimore, May 17, 2011 May, 2011
7. Adaptive epithelial cell immunoregulation with nanoemulsion mucosal adjuvant. Poster, Department of Internal Medicine 19th Annual Research Day, University of Michigan, Ann Arbor MI May 20, 2011. May, 2011
8. Development of a nanoemulsion-based therapeutic vaccine for hepatitis B virus Poster, Department of Internal Medicine 19th Annual Research Day, University of Michigan, Ann Arbor MI May 20, 2011 May, 2011
9. Nanoemulsion based adjuvant for intranasal influenza vaccine: characterization of humoral and cellular immune responses. Poster, Department of Internal Medicine 19th Annual Research Day, University of Michigan, Ann Arbor MI May 20, 2011. May, 2011
10. Nanoemulsion adjuvants enhance antigen uptake by epithelial and dendritic cells and facilitate phagocytosis of antigen-loaded cells by antigen presenting cells, in vitro Poster, Department of Internal Medicine 19th Annual Research Day, University of Michigan, Ann Arbor MI May 20, 2011. May, 2011
11. Nanoemulsion and the transcriptional regulation of Th17 cell differentiation and immunity. Poster, Department of Internal Medicine 19th Annual Research Day, University of Michigan, Ann Arbor MI May 20, 2011. May, 2011
12. Nanotechnology Moves Beyond the Clinic into the Marketplace Herbert D. Doan Nanotechnology Symposium, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, April 2011, Ann Arbor April, 2011
13. Nanotechnology: Overview and Applications of Interest to the Allergiest/Immunology. Invited speaker, AAAAI Military Allergy/Immunology Assesmby in conjuction with the 25th Annual Harold S. Nelson Allergy/Immunology Symposium, AAAAI Annual Meeting, San Francisco March, 2011
14. Nanotechnology for Cancer Approaches in the Clinic. Nanobiotechnology Seminar Series, Stanford University, School of Medicine, Department of Radiology, February 2011, Stanford January, 2011
15. Nanotechnology for the Enhancement of Human Health Nanotechnology and Integrated Microsystems Student Association (NIMSA), University of Michigan, December 2, Ann Arbor. December, 2010
16. Acetonitrile shortage: Evaluation of an alternative “green” isopropanol based reverse phase ultra pressure liquid chromatography eluent system to characterize PAMAM dendrimer based cancer therapeutics. Poster, greenUp Michigan Green Chemistry Conference, East Lansing, October 20, 2010. October, 2010
17. Nanoemulsion adjuvant enhances uptake and antigenicity of nasally administered proteins Poster, Grand Challenges in Global Health Meeting, Seattle, October 24-27, 2010 October, 2010
18. Nasal Adjuvanted Vaccine for Influenza Keynote Speaker, 6th Annual GCGH Meeting, October 25, Seattle. October, 2010
19. Enhance immune response in transgenic mice expressing proapoptotic bid in the thyroid. Oral Communication and Poster, 14th International Thyroid Congress 2010, Paris France, September 14, 2010 September, 2010
20. Nanotechnology Development Invited Speaker, National Intelligence University Program, Ross School of Business, University of Michigan, June 30, Ann Arbor June, 2010
21. Mechanism of humoral and cellular immune response with novel mucosal nanoemulsion adjuvant Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 14, 2010 May, 2010
22. Novel nanoemulsion formulations as potential adjuvant for mucosal influenza vaccine. Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 14, 2010. May, 2010
23. UM Technology Transfer and Commercialization Invited Speaker, The Rotary Club of Ann Arbor, May 12, Ann Arbor. May, 2010
24. Clinical Conflict of Interest Symposia; Academic/Industry Partnerships. Panelist, University of Michigan Health System, Ann Arbor MI, February 9, 2010 February, 2010
25. The Pharmaceutical Industry, What Is It Today and Did Government and Academia Create This Model. Invited Speaker, University of Michigan Scientific Club, February 10, Ann Arbor February, 2010
26. Cancer Applications of Nanoparticles Invited Speaker, University of Michigan Cancer Center Innovation Series, January 14, University of Michigan, Ann Arbor January, 2010
27. Prospects for Nanomedicine Keynote Speaker, Nanomedicine: Enterprise and Society, The Institute for Innovation & Entrepreneurship, University of Texas, January 22, Dallas. January, 2010
28. Dendrimer based Cancer Therapy Invited Speaker, 240th ACS National Meeting, Multifunctional Nanoparticles for Drug Delivery and Imaging, Division of Polymeric Materials: Science and Engineering, August 22, Boston January, 2010
29. Dendrimer-based Nanoparticles for Cancer Therapy Invited Speaker, American Society of Hematology (ASH), December 5, New Orleans December, 2009
30. Nanoemulsion Vaccines Plenary Speaker, International Vaccine Symposium, December 18, Brussels Belgium. December, 2009
31. Nanotechnology in Medicine and Biology Keynote Speaker, Nanotechnology Conference, IEEE, Southeastern Michigan Section, November 18, Ypsilanti MI November, 2009
32. Saccharide-functionalized polyvalent generation-3 poly(amidoamine) dendrimer-methotrexate conjugates as potential anticancer agents 4th Annual NCI Alliance for Nanotechnology in Cancer Investigators Meeting, Manhattan Beach CA, October 20-22, 2009 October, 2009
33. Dendrimer-based multivalent methotrexates as dual acting nanoconjugates in cancer cell targeting 4th Annual NCI Alliance for Nanotechnology in Cancer Investigators Meeting, Manhattan Beach CA, October 20-22, 2009. October, 2009
34. Synthesis and isolation of dendrimers with precisely defined numbers of functional ligands 4th Annual NCI Alliance for Nanotechnology in Cancer Investigators Meeting, Manhattan Beach CA, October 20-22, 2009 October, 2009
35. Targeted nanodendrimeric anticancer prodrug: conjugate of methotrexate, folic acid, and poly(amidoamine) dendrimer – a novel rapid ‘one pot’ synthetic approach 4th Annual NCI Alliance for Nanotechnology in Cancer Investigators Meeting, Manhattan Beach CA, October 20-22, 2009. October, 2009
36. Apoptosis in Experimental Autoimmune Thyroiditis Models Invited Speaker, Animal Models of Thyroid Autoimmunity, 80th Annual Meeting of the American Thyroid Association, September 26, Palm Beach FL September, 2009
37. Nanobiology. Invited Speaker, Pulmonary Research Lecture Series, Division of Pulmonary and Critical Care Medicine Core Research Training Program, University of Michigan, July 14, Ann Arbor MI July, 2009
38. Real-time, label-free protein binding detection with a one dimensional photonic crystal sensor Poster Presentation #CTuCC6, CLEO, Baltimore MD, May 31-June 5, 2009. June, 2009
39. Dendrimer Based Therapuetics Plenary Speaker, International Dendrimer Symposium 6 (IDS:6), KTH campus, June 14-18, 2009, Stockholm Sweden June, 2009
40. Nasal immunization with a nanoemulsion-based Burkholderia Cenocepacia outer membrane protein vaccine protects against experimental lung infections in mice Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009. May, 2009
41. Targeting efficacy of dendrimer-based nanotherapeutic in artificial heterogenous tumor model in vivo Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009 May, 2009
42. Immunogenic response in CD-1 mice immunized with a novel nanoemulsion adjuvanted influenza vaccine Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009 May, 2009
43. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009. May, 2009
44. Toll-like receptors 2 and 4 and CD80/CD86 signaling in the mechanism of mucosal nanoemulsion adjuvant Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor, May 14-15, 2009 May, 2009
45. Activation and nuclear translocation of transcriptional factor NF-κB with novel nanoemulsion adjuvant Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009 May, 2009
46. Medical Applications of Nanotechnology. Invited Speaker, The Second Milka Mukhova Montiel, MD Distinguished Lecture Series, Department of Pathology, The University of Texas Health Science Center at San Antonio, May 18, 2009, San Antonio TX May, 2009
47. An immune response to nanoemulsion-adjuvanted commercial vaccine in two species by using nasal route. Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009. May, 2009
48. Intranasal immunization with a plant produced recombinant H5 antigen and nanoemulsion adjuvant for the prevention of pandemic avian influenza. Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009 May, 2009
49. Nanotechnology in Biology and Medicine Invited Speaker, 12th International Symposium of Immunology 2009 – Infectious Agents: Immunobiology and Countermeasures, Los Alamos National Laboratory and Baylor College of Medicine, May 7, 2009, Sante Fe NM May, 2009
50. Differential modulation of gene expression with oil-in-water nanoemulsion mucosal adjuvants Poster, University of Michigan Department of Internal Medicine Annual Research Day, Ann Arbor MI, May 15, 2009 May, 2009
51. Oral presentation #S32, 12th Annual Conference on Vaccine Research, National Foundation for Infectious Diseases, Baltimore MD, April 29, 2009 April, 2009
52. Nasal administration of W805EC-adjuvanted influenza vaccine in mice. Poster Presentation #P13, 12th Annual Conference on Vaccine Research, National Foundation for Infectious Diseases, Baltimore MD, April 27-29, 2009. April, 2009
53. Nanoemulsion Adjuvant. World Vaccine Conference, April 18, 2009. Warrenton, VA. April, 2009
54. Translating Material Science into Pharmaceuticals Featured Speaker, Midwest Biomedical Engineering Conference (MBEC), University of Michigan, April 3, 2009, Ann Arbor MI April, 2009
55. W805EC, a nanoemulsion adjuvant, provides robust anti-influenza immunity in ferrets after a single immunization. Oral presentation #S4, 12th Annual Conference on Vaccine Research, National Foundation for Infectious Diseases, Baltimore MD, April 27, 2009 April, 2009
56. Nanotechnology for Therapeutic Initiatives Invited Speaker, Provost Interdisplininary Seminar Series on Targeted Therapeutics and Drug Delivery Systems, University of Pennsylvania, February 18, 2009, Philadelphia PA February, 2009
57. Innovations in Nanotechnology Research Invited Speaker, 2009 Michigan University Research Corridor Tour, August 20, Ann Arbor MI January, 2009
58. Label-free biosensing using a photonic crystal structure in a total-internal-reflection geometry. Proc. of SPIE 7188, 71880B, presented at BIOS, SPIE Photonic West, San Jose CA, 2009. January, 2009
59. The Dynamics of Spinning Off Companies from Academics Invited Speaker, Distinguished Innovator Seminar Series, Center for Entrepreneurship, University of Michigan College of Engineering, January 30, 2009, Ann Arbor MI January, 2009
60. Nanotechnology for Human Health. Invited speaker, 2008-2009 Innovators Seminar Series, Arizona State University, Biodesign Institute, December 11, 2008, Tempe AZ. December, 2008
61. Scientific Polymers for Human Therapeutics Invited Speaker, University of Michigan Exchange Program with Nagoya University on Macromolecular Chemistry, November 25, 2008, Ann Arbor MI. November, 2008
62. Nanotechnology for the Enhancement of Human Health Invited Speaker, Institute for Materials Research Colloquia Series, Ohio State University, November 12, 2008, Columbus OH. November, 2008
63. Nanoemulsion Therapeutics and Vaccines Invited speaker, Bill and Melinda Gates Foundation, November 5, 2008, Seattle WA. November, 2008
64. Panelist, Nanomedicine Session, MichBio Expo, Novi MI, November 25, 2008. November, 2008
65. Nanotechnology Applied to Human Health Keynote Speaker, Department of Medicine's 6th Annual Research Day, University of Colorado-Denver, November 1, 2008, Denver CO. November, 2008
66. A Novel Nanoemulsion Adjuvant Enhancing the Immune Respose to β-propiolactone Inactivated Influenza Virus Using a Nasal Route in a Ferret Model Poster Presentation #G-1194, 48th Annual Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington DC, October 25-28, 2008. October, 2008
67. Novel Nanoemulsion NB-001 Permeates Skin by the Follicular Route Poster Presentation #A-1898, 48th Annual Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington DC, October 25-28, 2008 October, 2008
68. Mechanism of Skin Penetration and Distribution of a Novel Nanoemulsion. Poster Presentation #M-2135, 48th Annual Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington DC, October 25-28, 2008 October, 2008
69. Evaluation of a Nanoemulsion Formulation with Rapid Antimicrobial Activity Against Planktonic and Biofilm Forms of Burkholderia cepacia and Pseudomonas aeruginosa Poster Presentation #B-3807, 48th Annual Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington DC, October 25-28, 2008. October, 2008
70. Nanoemulsions as Adjuvants for Nasal-spray Vaccines 4th Annual Grand Challenges in Global Health Meeting, October 19-22, 2008, Bangkok Thailand October, 2008
71. Two photon fluorescence biosensing through a dual-clad optical fiber. IMAT Meeting, Boston MA, October 2008. October, 2008
72. Subject-assessed Time to Healing in a Randomized, Double-blind, Vehicle-controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis Poster Presentation #V-3771, 48th Annual Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington DC, October 25-28, 2008. October, 2008
73. Safety, Tolerability and Pharmacokinetics of NB-001 in a Phase 2 Dose Ranging Trial in Subjects with Recurrent Herpes Labialis Poster Presentation #V-3539, 48th Annual Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, Washington DC, October 25-28, 2008 October, 2008
74. Nanotechnology for the Enhancement of Human Health Plenary Speaker, 29th Congress of the Italian Society of Pathology (SIP) in collaboration with the American Society for Investigative Pathology (ASIP), September 10-13, 2008, Rende Italy September, 2008
75. Nanotechnology Applied to Human Health Dean's Distinguished Lecturer, Harper Boyd Lecture, Univ of Arkansas for Medical Science, September 23, 2008, Little Rock AR. September, 2008
76. Biological Aspects of Nanotechnology . Invited speaker, NanoCBW conference, June 18, 2008, Chantilly VA June, 2008
77. Multi-functional Nanotechnology Systems for Cancer Therapy Invited speaker, 40th Regular Meeting of the Board of Scientific Advisors, National Cancer Institute, June 23, 2008, Bethesda, MD June, 2008
78. Nanotechnology, Nanomolecular Materials and Nanomedicine Invited speaker, Concurrent Symposia: Nanomedicine: Can Tiny Devices Solve Big Problems in Transplantation? American Transplant Congress, June 1, 2008, Toronto, ON, Canada. June, 2008
79. Development of a Novel Nanoemulsion-based Hepatitis B Mucosal Vaccine Poster Presentation, 11th Annual Conference on Vaccine Research, NFID, Baltimore MD, May 5, 2008. May, 2008
80. Insights into the Mucosal Adjuvant Mechanism of a Soybean Oil Nanoemulsion (SO-NE): Participation of GM1 Ganglioside Poster Presentation, #S20, 11th Annual Conference on Vaccine Research, NFID, Baltimore MD, May 7, 2008 May, 2008
81. Optical biosensor based on one-dimensional photonic crystal in a total-internal-reflection geometry Poster Presentation #CThZ3, CLEO, San Jose CA, May 4-9, 2008 May, 2008
82. Development of Mucosal Vaccines against Category A Pathogens based on a Novel Nanoemulsion Adjuvant Poster Presentation, Department of Internal Medicine Annual Research Symposium, May 23, 2008 May, 2008
83. Characterization of Immune Response to a Novel Nanoemulsion-based Mucosal Vaccine against Bacillus anthracis, Yersinia pestis and Clostridium botulinum. Poster Presentation, Department of Internal Medicine Annual Research Symposium, May 23, 2008 May, 2008
84. Nanotechnologies for Healthcare Invited Speaker, Medical Devices and Medical Division Comprehensive Care & Surgical Care Research & Development and Operations Review Meetings, Johnson & Johnson, May 20, 2008, Basking Ridge NJ May, 2008
85. Nanotechnology for the Enhancement of Human Health Plenary Speaker, American Association of Dental Research Symposium, April 2, 2008, Dallas TX April, 2008
86. Why Nanotechnology is Important to Medicine. Featured speaker, F.A. Bourke Distinguished Lecture in Biotechnology, Center for Advanced Biotechnology, Boston University, April 28, 2008, Boston MA April, 2008
87. Design of Multifunctional Drug Delivery Platforms via Combinatorial Synthesis Poster, Poly 106, 235th ACS National Meeting, New Orleans LA, April 6-10, 2008. April, 2008
88. Design of Binary Codendrons for Targeted Drug Delivery Poster, Poly 504, 235th ACS National Meeting, New Orleans LA, April 6-10, 2008. April, 2008
89. Poly(amidoamine) Dendrimer-based Multifunctional Engineered Nanodevice for Cancer Therapy Poster Presentation, PMSE 423, 235th ACS National Meeting, New Orleans LA, April 6-10, 2008 April, 2008
90. Nasal Immunization with a Novel Nanoemulsion Adjuvant Modifies Th2-Polarized Immune Responses. Abstract, American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, Philadelphia PA, March 15-18, 2008 March, 2008
91. Nanotechnology Applications to Allergy and Asthma Workshop Discussion Leader, American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, Philadelphia PA, March 18, 2008. March, 2008
92. Nanotechnology: The Medicine of the Future…Today Plenary Speaker, 2008 Association of Professors of Medicine (APM), March 1, Miami FL. March, 2008
93. Strategic Workshop on Cancer Nanotechnology: Therapy and Post-Treatment Strategic Workshop on Cancer Nanotechnology: Therapy and Post-Treatment March, 2008
94. Nanotechnology Applications to Allergy and Asthma Therapy Speaker, American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, March 18, 2008, Philadelphia PA. March, 2008
95. Curing Cancer from the Inside Out Michigan Difference Campaign, University of Michigan, February 7, Sarasota, FL February, 2008
96. What is Nanomedicine? Featured speaker, 12th Annual Roy H. Behnke Distinguished Lectureship and 18th Annual 2008 USF Health Research Day, University of Southern Florida, February 22, Tampa FL February, 2008
97. Quantitative Studies of Multivalent Polymers Designed for Targeted Drug Delivery Special Lecture, Department of Polymer Science, University of Akron, January 17, Akron OH January, 2008
98. What is Nanomedicine? Program in Excellence in Nanotechnology (PEN): Integrated Nanosystems for Diagnosis and Therapy Siteman Center of Cancer Nanotechnology Excellence (SCCNE), Washington University Medical Campus, January 22, St. Louis MO January, 2008
99. Dendrimer-based Nanomedicine Pan Stanford Publishing Pte. Ltd. Singapore, 2008. January, 2008
100. The Uncertain Future of Vaccines Medical Grand Rounds, Department of Medicine, University of Michigan, January 11, Ann Arbor MI January, 2008
101. Increased production of IL-4 and IL-10 cytokines in EAT mice treated by TRAIL. 79th Annual Meeting of the American Thyroid Association, Chicago IL, 2008 January, 2008
102. 2-methoxyestadiol exhibits an inhibitory effect on anaplastic thyroid cancer cell in a mouse xenograft tumor model. 90th Annual Meeting of the Endocrine Society, San Francisco CA, 2008 January, 2008
103. Challenges in Biodefense Research Symposium on Future Directions in Research at the Intersection of the Physical and Life Sciences (RIPLS), The National Academies, December 19, Washington DC December, 2007
104. Immunogenicity of an Experimental Trivalent Nanoemulsion-based Nasal Vaccine against Anthrax, Plague and Botulinum Toxin. Abstract, GLRCE Annual Meeting, Hilton Head NC, November 29-December 1, 2007 December, 2007
105. Nanoemulsions as Adjuvants for Nasal-Spray Vaccines Workshop on Vaccine Technologies: Needle Free Delivery, Aerosol Delivery and Nanoparticles – Challenges of Global Vaccine Development, Keystone Symposia, October 10, Cape Town, South Africa October, 2007
106. Nanoemulsions as Adjuvants for Nasal-spray Vaccines 3rd Annual Grand Challenges in Global Health Meeting, October 7-9, Cape Town, South Africa October, 2007
107. Universities and the Biotechnology/Biomedical Sector Workshop Discussion Leader, The Role of Engaged Universities in Economic Transformation, Regional Conference by National Academies Study, “Rising Above the Gathering Storm”, Ann Arbor MI, October 16, 2007 October, 2007
108. Nanotechnology – Path to the Clinic: Promises and Hurdles Plenary Talk, NCI Alliance for Nanotechnology in Cancer Investigators Meeting, National Cancer Institute, October 17-18, Chapel Hill NC October, 2007
109. Nanotechnology for the Enhancement of Human Health Lyons Memorial Lecturer, 2007 Annual Session of the American Association of Oral & Maxillofacial Surgeons, October 13, Honolulu HI October, 2007
110. Nanotechnology Approaches to Microbiology and Vaccines Keynote Lecture, Department of Microbiology and Immunology Annual Retreat, October 21, Roscommon MI October, 2007
111. Dendrimers in Drug Delivery Symposium on Molecular Diversity in Drug Design, Discovery and Delivery, University of South Florida, October 26, Tampa FL October, 2007
112. Nanotechnology for the Enhancement of Human Health. Nano @Wayne Seminar Series, Wayne State University, September 18, Detroit MI. September, 2007
113. Application of a Sensitive Double-clad Optical Fiber for Two-photon Fluorescence Measurement in Tissues 8th Principal Investigators Meeting for the IMAT Program, July 24-25, Redwood City CA July, 2007
114. The Future of Biological Threats Panelist, Biointelligence: Intelligence in the Era of Big Biology, Intelligence Science Board (ISB) Quarterly Meeting (MITRE), McLean VA, June 12, 2007. June, 2007
115. Nanoemulsions as Adjuvants for Nasal-spray Vaccines Grand Challenges in Global Health Meeting, June 13-14, Boulder CO. June, 2007
116. Nanotechnology for the Enhancement of Human Health Plenary Speaker, The Endocrine Society's 89th Annual Meeting, Endo 2007, June 2-5, Toronto, Ontario, Canada June, 2007
117. Nanotechnology for the Enhancement of Human Health Keynote Speaker, 2nd Annual Cancer Nanobiology Think Tank, CCR Nanobiology Program, National Cancer Institute (NCI), Frederick MD May, 2007
118. The Intersection of Nanotechnology, Microelectronics and Regenerative Medicine. Track: Device and Predictive Diagnostics Panelist, 2007 BIO International Convention, Boston MA, May 24, 2007. May, 2007
119. Town Hall Meeting on University of Michigan Efforts to Enhance Relationships with Industry Panelist, University of Michigan, Office of the Vice President for Research, Ann Arbor, May 31, 2007 May, 2007
120. Nanotechnology in Medicine Keynote Speaker, University of Florida, College of Medicine Research Day 2007, Gainesville FL March, 2007
121. Nanoparticle Based Cancer Therapy Division of Hematology/Oncology Research Conference, University of Michigan, Ann Arbor MI March, 2007
122. Nanotechnology: The Power of Small – Nano-Medicine: Human Health & Enhancement. Panelist, Fred Friendly Seminars, Columbia University, Graduate School of Journalism, SCETV, Columbia SC, March 24, 2007. March, 2007
123. Nanotechnology for the Enhancement of Human Health National Institute of Standards and Technology (NIST) Colloquium Series, NIST, Gaithersburg MD March, 2007
124. Nanomedicine MSTP Program, University of Michigan, Ann Arbor MI March, 2007
125. Nanotechnology and Biomedical Applications Moderator, Nanotechnology, Novel Drug Delivery and Asthma Therapy Workshop, Session 5710, 2007 Annual American Academy of Allergy Asthma & Immunology (AAAAI), San Diego CA February, 2007
126. Nanotechnology, Novel Drug Delivery and Asthma Discussion Leader, 2007 Annual American Academy of Allergy Asthma and Immunology (AAAAI) Meeting, San Diego CA, February 23-27, 2007 February, 2007
127. Nanotechnology for the Enhancement of Human Health. Health Fontiers in Nanotechnology Seminar Series, International Institute for Nanotechnology, Northwestern University, Evanston IL February, 2007
128. Nanoparticle-membrane interactions: The effects of dendrimber terminal chemistry on targeted drug delivery, gene therapy, and toxicity Abstract, Biophys J 192A-192A Suppl. S, Jan 2007 January, 2007
129. Dendrimers in Drug Delivery Plenary Speaker, 5th International Dendrimer Symposium (IDS:5), August 29, Toulouse France January, 2007
130. Nanomedicine: Current Status and Future Prospects Washtenaw County Medical Society, Ann Arbor MI November, 2006
131. DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment Nanotechnology in Society and Manufacturing Session, 2006 Industrial Physics Forum, San Francisco CA November, 2006
132. Nanotechnology and Vaccines The Changing Landscape of Vaccine Development: Vaccines for Global Health, Galveston TX November, 2006
133. Nanoemulsions as Adjuvants for Nasal-Spray Vaccines. Grand Challenges in Global Health, Washington DC October, 2006
134. Combinatorial synthesis of targeted drug delivery platforms Poster Session, NCI Alliance for Nanotechnology in Cancer Investigators Meeting, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, La Jolla CA, October 24-25, 2006. October, 2006
135. DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment. 7th Annual Targeted Nanodelivery: Enabling Targeted Therapies and Non-Invasive Imaging, Baltimore MD October, 2006
136. Nanotechnology and the Implications for Vaccine Development ITIC Fall 2006 Molecular Biology Seminar, McLean VA October, 2006
137. Nanotechnology in Drug Delivery NCI Alliance for Nanotechnology in Cancer Investigators Meeting, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, La Jolla CA October, 2006
138. New Fiberoptic Technology for the Detection of Biomarkers in Tissue 7th Principal Investigators Meeting for the IMAT Program, Bethesda MD September, 2006
139. Nanotechnology in society and its impact on business & industry Panel Discussion, Nanotechnology in Science & Society Symposium, Michigan Nanotechnology Institute for Medicine & Biological Sciences, University of Michigan, Ann Arbor MI, September 8-9,2006 September, 2006
140. Interesting Cases & Panel Discussion Panel Discussion, John M. Sheldon Society 2006 Summer Mtg, Boyne Mtn MI, July 8-9, 2006 July, 2006
141. Nanotechnology in Medicine: The Next Frontier . John M. Sheldon Society 2006 Summer Mtg, Boyne Mtn MI. July, 2006
142. Dendritic Nanodevices. Alternative Therapeutic Approaches to Endocrine Cancer 2006 Endocrine Society Meeting, Boston MA June, 2006
143. Dendrimer Based Therapeutic and Imaging Agents Immunology Seminar-Department of Pathology, University Medical Center, Ohio State University, Columbus OH May, 2006
144. Quantitative Polyvalent Interactions Between Single Molecules Single Molecule Symposium, University of Michigan, Ann Arbor MI May, 2006
145. Key indications/sectors (role of academic research). Panel Discussion, National Academies Committee on a New Government-University Partnership for Science and Security, MIT, Cambridge MA, May 15-16, 2006 May, 2006
146. Nanoparticle Therapeutics: Size Matters 1st Annual Chapel Hill Drug Conference & 10th Annual Liposome Research Days Conference, Chapel Hill NC May, 2006
147. Will Nanomedicine Save Your Life? Medicine at Michigan: Coast to Coast Seminars 2006, Scottsdale AZ and La Quinta CA April, 2006
148. Nanotechnology Applications in Drug Delivery. BIO 2006 Chicago Annual International Convention, Chicago IL April, 2006
149. Career paths in biomedical engineering-alternative careers. Presented, 2006 Midwestern Biomedical Engineering Conference, University of Michigan, Ann Arbor MI, March 24, 2006 March, 2006
150. Translating Biomakers into Cancer Diagnostics and Therapeutics. NCI 4th Annual Early Detection Research Network Scientific Workshop, Philadelphia PA March, 2006
151. Career Paths in Biomedicla Engineering-Alternative Careers 2006 Midwestern Biomedical Engineering Conference, University of Michigan, Ann Arbor MI March, 2006
152. 2006 American Association for the Advancement of Science Annual Meeting, St. Louis MO 2006 American Academy of Allergy, Asthma and Immunology, Miami Beach FL February, 2006
153. Targeting Cancer Cells Using Dendrimers 2006 American Association for the Advancement of Science Annual Meeting, St. Louis MO February, 2006
154. Nanotechnology for the Enhancement of Human Health University of Medicine & Dentistry of New Jersey, Newark NJ. January, 2006
155. Unique genetic expression in nasal mucosa and blood of patients with nasal polyposis and inflammatory nasal conditions Abstract, AAAAI – American Academy of Allergy Asthma & Immunology, Miami Beach FL, March 2006; J Allergy Clinical Immunology 117(2):S73-S73 285 Suppl S Feb 2006 January, 2006
156. Real-time fluorescence measurement of a tumor-targeted nanodevice by a two-photon optical fiber fluorescence probe Photonics West, BIOS, San Jose CA, January 21-26, 2006 January, 2006
157. Nanotechnology Approaches to Cancer Diagnosis and Treatment Distinguished Lecture, George Washington University, Cancer Institute, Washington DC January, 2006
158. Nanotechnology Applications for Medicine and Iinfectious Diseases Association of Medical School Microbiology and Immunology Chairs Annual Meeting, Los Cabos, Baha Sur Mexico. January, 2006
159. What is Nanomedicine? Targeted Imaging and Therapeutics Group Discussion, New York Academy of Sciences, New York, NY December, 2005
160. Nanodevices for Noninvasive Detection, Diagnosis and Treatment of Cancer. AACR Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Philadelphia PA November, 2005
161. Nanotechnology Applications for Biology and Medicine Ophthalmology Grand Rounds, Kresge Hearing Institute, University of Michigan. November, 2005
162. The Promise of Nanomedicine Michigan Difference Campaign, University of Michigan, Ann Arbor MI October, 2005
163. Nanobiotechnology. Calculation to Communication Symposium, University of Michigan School of Public Health Center for Risk Science & Communication, Ann Arbor MI September, 2005
164. Bio-Nano Frontiers Panel Discussion Emerging Technologies Conference, MIT, Cambridge MA. September, 2005
165. Dendritic Devices Workshop on Characterization of Nanomaterials for Medical and Health Applications”, sponsors: ASTM, NCI, NIST and U.S. FDA, Reno NV May, 2005
166. Double-clad photonic-crystal-fiber based scanning microscopy CLEO/QELS, Baltimore MD, May 22-27, 2005 May, 2005
167. Multiphoton in vivo flow cytometry CLEO/QELS, Baltimore MD, May 22-27, 2005. May, 2005
168. Nanotechnology Applications for Biology and Medicine NIAID Grand Rounds, NIH Campus, Bethesda MD. May, 2005
169. Nanotechnology: Promise and Potential. NIH STEP Forum, National Institutes of Health, Bethesda MD April, 2005
170. Preparation and characterization of multifunctional dendrimer nanodevices for cancer therapy 13th Annual Department of Internal Medicine Research Symposium, P 31, April 29-30, 2005 Ann Arbor, Michigan April, 2005
171. HPLC analysis of poly(amidoamine) dendrimer derivatives, folate-conjugates, and their binding with a specific protein 13th Annual Department of Internal Medicine Research Symposium, P 76, April 29-30, 2005, Ann Arbor, Michigan. April, 2005
172. Tumor angiogenic vasculature targeting with PAMAM dendrimer–RGD conjugates. 13th Annual Department of Internal Medicine Research Symposium, University of Michigan, April 29-30, 2005. April, 2005
173. Tumor targeting of dendrimer-antibody conjugates University of Michigan Medical School Research Symposium, Ann Arbor, April 2005 April, 2005
174. The Changing Bioterror Threat over the Next Five Years Emerging Technologies for Developing and Disseminating Biological Organisms session, Emerging Technologies: Assessing the Future Bioterror Threat Conference, Centra Technologies for The Department of Homeland Security, Arlington VA April, 2005
175. Nanotechnology for the Enhancement of Human Health Emerging Technologies and Partnerships in Drug Delivery Conference, Philadelphia PA April, 2005
176. Nanotechnology for the Enhancement of Human Health The Department of Pharmaceutical Sciences, Wayne State University, Detroit MI April, 2005
177. The Future of Nanotechnology in Medicine The Ann Arbor Economic Club, Michigan League, University of Michigan, Ann Arbor MI April, 2005
178. Nanotechnology in Biology and Medicine 13th Annual Spring Research Day Symposium, The University of Virginia-Charlottesville, Charlottesville VA April, 2005
179. Nanomaterials for Biological and Medical Applications Plenary Session III and Oral Abstract Presentations, Translational Application of New Technologies, NIH Clinical Research Meeting, Washington DC April, 2005
180. Two-photon flow cytometry. Proceedings of SPIE Volume: 5700, Mar 2005 p. 78-89 March, 2005
181. Nanotechnology for the Enhancement of Human Health. FDA Workshop on Nanotechnology, Rockville MD. March, 2005
182. Synthesis and Functional Evaluation of DNA-assembled Polyamidoamine Dendrimer Clusters for Cancer Cell Specific Targeting 229th American Chemical Society Spring National Meeting, Anaheim CA. March, 2005
183. Nanotechnology for the Enhancement of Human Health The Society of Analytical Chemists of Pittsburgh, Pittsburgh PA February, 2005
184. Nanotechnology in Biology and Medicine North Carolina Society of Toxicology Spring Meeting, Research Triangle Park NC February, 2005
185. Effects of metabolic inhibitors on dendrimer nanoparticle-mediated endocytosis: active transport vs. nanoscale hole formation. 32nd Annual Spring Symposium Michigan Chapter of American Vacuum Society, East Lansing MI, 2005. January, 2005
186. Advances in Dendrimer-based Nanomedicine International Congress of Nanotechnology, San Francisco, CA January, 2005
187. Medical Applications for Nanotechnology Medical Grand Rounds, St. John's Hospital, Detroit MI. January, 2005
188. Nanoparticles in Human Beings Arizona Biodesign Workshop, Arizona State University, Phoenix AZ. January, 2005
189. Nanotechnology for the Enhancement of Human Health Parker H. Petit Institute for Bioengineering & Bioscience, Georgia Institute of Technology, Atlanta GA January, 2005
190. What is Nanomedicine? Keynote Lecture, The American Academy of Nanomedicine's First Annual Meeting, Johns Hopkins University, Baltimore MD January, 2005
191. Two-photon flow cytometry Photonics West Biomedical Optics Conference, San Jose CA, January 2005 January, 2005
192. Interactions of PAMAM dendrimers with cells: dependence of surface groups and relationship with lipid raft mediated endocytosis MRS Fall Meeting, 2005 Boston MA January, 2005
193. The role of polyvalency in targeted drug delivery MRS Fall Meeting, 2005 Boston MA January, 2005
194. Functionalization of G7 PAMAM dendrimers and their interaction with cells: possible mechanisms of dendrimer internalization 29th Macro Annual Symposium, Ann Arbor MI, 2005 January, 2005
195. Polyvalent targeting of G5 PAMAM based cancer cell targeting nanodevices: from preparation and characterization to binding study using SPR 29th Macro Annual Symposium, Ann Arbor MI, 2005. January, 2005
196. PAMAM dendrimer-mediated endocytosis: effect of temperature and surface end groups of the macromolecules 6th National Graduate Research Polymer Conference, Amherst MA, 2005. January, 2005
197. The interactions of polycations with model membranes 229th ACS National Meeting, San Diego CA, 2005. January, 2005
198. Interaction of polycationic polymers with cells and supported DMPC lipid bilayers. 6th National Graduate Research Polymer Conference, Amherst MA, 2005. January, 2005
199. Two-photon flow cytometry photonics west Bios 2005, San Jose CA, January 22-27, 2005 January, 2005
200. Quantitative two-photon flow cytometry CLEO/QELS and PhAST 2005, OSA, Washington DC, 2005, JThE35 January, 2005
201. Multiphoton in vivo flow cytometry. PhAST 2005, OSA, Washington DC, 2005, CFF1 January, 2005
202. Effects of metabolic inhibitors on polyamidoamine (PAMAM) dendrimer-mediated endocytosis: active transport vs. nanoscale hole formation 229th ACS National Meeting, San Diego CA, 2005. January, 2005
203. Development of a dual-clad photonic-crystal-fiber based scanning microscope Photonics West, Bios 2005 San Jose CA, January 22-27, 2005. January, 2005
204. Report of the Immune Working Group on Nanotoxicology Developmental Approaches for Evaluation of Toxicological Interactions of Nanoscale Materials, University of Florida, Gainesville FL November, 2004
205. Nanotechnology for the Enhancement of Human Health. 1232nd Meeting of the Milwaukee Academy of Medicine, Milwaukee WI. November, 2004
206. Nanotechnology for the Enhancement of Human Health Nanoscale Science & Engineering Plenary Lecture, Nanoscale Science & Engineering Forum, American Institute of Chemical Engineers Annual Meeting, Austin TX November, 2004
207. Regulation of Apoptosis Ernest L. Mazzaferri Translational Thyroid Cancer Conference, Ohio State University, Columbus OH November, 2004
208. In vivo flow cytometry. OSA Meeting, Rochester NY, Oct. 2004 October, 2004
209. Toward Partnerships Plenary Session Cancer Nanotechnology Symposium: Overcoming Barriers to Collaboration, Cleveland OH October, 2004
210. Dendrimer Therapeutics Drug Delivery Session, NanoMedicine Summit, The Cleveland Clinic, Cleveland OH October, 2004
211. Design, synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell specific targeting. 16th Macromolecular Science and Engineering Annual Research Symposium, University of Michigan, Ann Arbor, Oct 2004 October, 2004
212. Identification of genes regulated by IFN&gamma and IL-1&beta in thyroid epithelium cells Poster, 76th Annual Meeting of the American Thyroid Association, Vancouver, British Columbia September, 2004. September, 2004
213. In vivo quantitative biosensing based on multiphoton excitation SPIE-Optical Imaging Meeting, Bethesda MD, September 20–22, 2004. September, 2004
214. Biomedical Research and Nanotechnology Internal Medicine Grand Rounds, University of Michigan July, 2004
215. Nanomolecular Biosensors and Therapeutics Strategic Research to Enable NASA’s Exploration Missions, NASA Glenn Research Center National Center for Micro-Gravity Research on Fluids and Combustion, Cleveland OH June, 2004
216. Nanomaterial Therapeutics for Biodefense NIAID Biodefense Workshop, Nanobiology Strategies for Understanding the Immune System, Gaithersburg MD June, 2004
217. Dendrimers as a Platform for Drug Delivery Novel Tumor-Targeted Drug Delivery Systems Symposium, American Association of Pharmaceutical Scientists Pharmaceutics (AAPS) and Drug Delivery Conference, Philadelphia PA June, 2004
218. Dendrimer drug delivery: molecular inclusion vs. covalent conjugation Department of Internal Medicine 12th Annual Research Symposium, University of Michigan, Ann Arbor MI, May 7-8, 2004. May, 2004
219. Quantitative, in vivo fluorescence measurements with a two-photon fiber probe. Poster presentation, CLEO/IQEC Conference, San Francisco CA, May 16-21, 2004. May, 2004
220. Trapping cavitation bubbles with a self-focused laser beam CLEO/IQEC conference, San Francisco CA, May 16-21, 2004 May, 2004
221. An atomic force microscopy investigation of early morphological changes during apoptosis AVS Spring Symposium, Wayne State University, May 17, 2004 May, 2004
222. Engineered nanodevice for drug delivery into tumor cells: design, synthesis, characterization and functionality Poster presentation, University of Michigan Medical School Research Symposium, Ann Arbor, May 2004. May, 2004
223. Potential Health Applications of Nanotechnology NIH Nanomedicine Roadmap Initiative, NIH Campus, Bethesda MD. May, 2004
224. Targeting of folate-dendrimer MRI contrast agent to tumor xenografts expressing folate receptor Department of Internal Medicine 12th Annual Research Symposium, University of Michigan, Ann Arbor MI, May 7-8, 2004 May, 2004
225. Targeting, internalization and trafficking of the dendrimer-herceptin-dye conjugate in vitro Department of Internal Medicine 12th Annual Research Symposium, Ann Arbor MI, May 7-8, 2004 May, 2004
226. Near-field scanning optical microscopy of targeting and delivery of herceptin. First place poster, 31st Spring Symposium of the Michigan Chapter of the American Vacuum Society, Wayne State University, Detroit MI, May 17, 2004. May, 2004
227. Design of DNA-linked Poly(amidoamine) (PAMAM) Dendrimer Nanoclusters for Tumor-specificTargeting University of Michigan Medical School Research Symposium, Ann Arbor. May, 2004
228. RNA Aptamers Selectively Target PSMA-Positive NLCap Cell Line Presented, Department of Internal Medicine Research Symposium 2004, The University of Michigan, Ann Arbor MI, May 7-8, 2004 May, 2004
229. Nanoparticle Targeting of Tumors Measured by Two Photon Optical Fiber Fluorescence Probe University of Michigan Medical School Research Symposium, Ann Arbor MI May, 2004
230. Quantitative, in vivo Fluorescence Measurements with a Two-photon Fiber Probe 2004 CLEO/IQEC Conference, San Francisco CA May, 2004
231. Nanotechnology for Drug Delivery and Targeted Imaging Nanotechnology Session, FDA Science Forum, Washington DC. May, 2004
232. The Immunologic Basis of Primary Immune Deficiency. Michigan Immuno-Deficiency Foundation Spring Meeting, University of Michigan, Ann Arbor MI. April, 2004
233. The Confluence of Science and Commercialization Panel Moderator, BioMed Expo 2004, Eastern Michigan University, Ann Arbor MI April, 2004
234. Nanotechnology for Medical Applications First Annual Asa Gray Lectureship, University Commons, Ann Arbor MI. April, 2004
235. Bioterrorism Agenda Co-Moderator, Breakfast Seminar, 61st Meeting of the American Academy of Allergy, Asthma and Immunology, San Francisco CA March, 2004
236. Vaccines as Causes of Autoimmunity: Pros & Cons 61st Meeting of the American Academy of Allergy, Asthma and Immunology, San Francisco CA March, 2004
237. Nanomedicine for Cancer NCI Nanotechnology: Visualizing and Targeting Cancer Symposium, Salk Institute for Biological Studies, La Jolla CA. March, 2004
238. Nanomolecular Therapeutics Seminar, Arizona Biodesign Institute, Arizona State University, Phoenix AZ March, 2004
239. Contemporary Challenges in Vaccination Moderator, 61st Meeting of the American Academy of Allergy, Asthma and Immunology, San Francisco CA. March, 2004
240. Biodefense. Nanotechnology in Health Sciences, Nanotech 2004, Nano Science and Technology Institute, Boston MA March, 2004
241. Bioterrorism. Medical Grand Rounds, St. Joseph Mercy Hospital, Ypsilanti MI March, 2004
242. Emerging Infectious Diseases: Biothreat Agents Speaker & Co-Moderator, 61st Meeting of the American Academy of Allergy, Asthma and Immunology, San Francisco CA. March, 2004
243. End group effects of polyamidoamine (PAMAM) dendrimers on membranes. 31st Annual Spring Symposium Michigan Chapter of American Vacuum Society, Detroit, MI, 2004 January, 2004
244. An atomic force microscopy study of early morphological changes during apoptosis 31st Annual Symposium of the Michigan Chapter of the American Vacuum Society: Advances and Applications in Scanning Probe Microscopy, Detroit MI, May 2004 January, 2004
245. Engineered dendrimer based nanodevice for drug delivery into tumor cells: design, synthesis, characterization and functionality 228th ACS National Meeting, August 22-26, 2004, Philadelphia PA. January, 2004
246. Surface effect of polyamidoamine (PAMAM) dendrimers on model and cell membranes 12th Annual Research Symposium of Internal Medicine at Michigan, University of Michigan, Ann Arbor MI, 2004. January, 2004
247. Two-photon fluorescence biosensing with conventional and photonic crystal fibers Photonics West BIOS conference, San Jose CA, January 24-29, 2004 January, 2004
248. Polycation induced nano-scale hole formation in model and cell membranes 28th Macro Annual Symposium, Ann Arbor MI, 2004. January, 2004
249. Medical Applications of Nanotechnology Henry Russel Lecturer’s Dinner, The Michigan League, University of Michigan, Ann Arbor MI December, 2003
250. Interaction of dendritic polymers with lipid bilayers relationship between molecular architecture and biologic activity Frontiers in Nanoscience and Nanotechnology Symposium, Ann Arbor MI, November 15, 2003 November, 2003
251. Interaction of Dendritic Polymers with Lipid Bilayers, Relationship Between Molecular Architecture and Biologic Activity Frontiers in Nanoscience and Nanotechnology Symposium, Ann Arbor MI. November, 2003
252. Interaction of Dendritic Polymers with Lipid Bilayers: Relationship Between Molecular Architecture and Biologic Activity Frontiers in Nanoscience and Nanotechnology Symposium, Ann Arbor MI November, 2003
253. Nanotechnology for the Enhancement of Human Health Frontiers in Nanoscience and Nanotechnology Symposium, University of Michigan, Ann Arbor MI November, 2003
254. Biomedical Perspective. Plenary Speaker on Nanotechnology to Enhance Human Health, National Nanotechnology Initiative Workshop on Biotechnology, Arlington VA October, 2003
255. Nanotechnology for Medical Applications MIT-Stanford-Berkeley Nanomedicine Forum, Stanford University, Stanford CA October, 2003
256. Nanomolecular Therapeutics The University of Florida, Gainesville Florida October, 2003
257. Nanomolecular Therapeutics Medical Grand Rounds, Oklahoma University, Department of Medicine, Oklahoma City OK. September, 2003
258. Characterization of poly(amidoamine) dendrimers by capillary electrophoresis. Analytical Division Poster Session, Division of Analytical Chemistry, The 226th ACS National Meeting, New York NY, September 7-11, 2003 September, 2003
259. Synthesis and in vitro Testing of Antibody-dendrimer Conjugates for Targeted Cancer Therapy 3rd International Dendrimer Symposium, Berlin Germany September, 2003
260. Synthesis and Characterization of Novel POPAM-PAMAM (POMAM) Hybrid Dendrimers as Reactive Modules for Biologic Nanodevice Construction 6th Austrian Polymer Meeting, XXIst International H. F. Mark-Symposium, Austria, Vienna. September, 2003
261. Bioterrorism. Intermountain West Allergy Association’s 6th Annual Scientific Session, Coeur d’Alene ID July, 2003
262. Molecular Engineering in Nanotechnology: Design, Synthesis, Characterization and Biological Studies of PAMAM Dendrimer Based Multifunctional Cancer Therapeutics Gordon Conference: Chemistry of Supramolecules and Assemblies, Andover NH July, 2003
263. Molecular Engineering in Nanotechnology: Design, Synthesis, Characterization, and Biological Studies of PAMAM Dendrimer Based Multifunctional Cancer Therapeutics Gordon Conference, New Orleans July, 2003
264. Two-photon in vivo flow cytometry 2nd Principal Investigators Meeting Joint NCI-NASA Fundamental Technologies for Biomolecular Sensors Program, Chicago Illinois, July 28-29, 2003 July, 2003
265. Nanotechnology for Therapeutics The Center for the Integration of Medicine and Innovative Technology (CIMIT) Forum Series on Nanotechnology, Massachusetts General Hospital, Cambridge MA. July, 2003
266. Acoustic detection of microbubble formation in enhanced optical breakdown of silver/dendrimer nanocomposites Conference on Lasers and Electro-Optics, June 1-6, 2003. June, 2003
267. Enhanced Biosensing Using Photonic Crystal Fibers Conference on Lasers and Electro-optics June, 2003
268. Nanotherapeutics for Cancer. Van Andel Research Institute Seminar Series, Van Andel Research Institute, Grand Rapids MI June, 2003
269. Acoustic Detection of Microbubble Formation in Enhanced Optical Breakdown of Silver/Dendrimer Nanocomposites Conference on Lasers and Electro-Optics June, 2003
270. Targeted drug delivery using multifunctional synthetic dendrimer nanodevice Center for Biologic Nanotechnology, University of Michigan Medical School, Ann Arbor MI, Research Symposium May 9-10, 2003. May, 2003
271. Interaction of Dendritic Polymers with Lipid Bilayers, Relationship Between Molecular Architecture and Biologic Activity. 30th Annual Spring symposium, Michigan Chapter of AVS, Ann Arbor MI. May, 2003
272. Targeted Drug Delivery to Tumor Cells Through the Folate Receptor Using Dendrimer-based Therapeutic Nanodevice in vivo Department of Internal Medicine 11th Annual Research Symposium, Ann Arbor, MI May, 2003
273. Nanomolecular Therapeutics Houston/Galveston Lecture Series Visiting Professor, Pfizer Pharmaceuticals, Houston & Galveston TX. May, 2003
274. Dendrimer based cell-permeant mitochondrial probe for monitoring radiation-induced programmed cell death. University of Michigan Medical School, Ann Arbor MI, Research Symposium, May 9-10, 2003 May, 2003
275. Synthesis and in vitro evaluation of antibody-dendrimer conjugates for cell imaging and targeted drug delivery to cancer Abstract Presentation, University of Michigan Medical School, Ann Arbor MI, Research Symposium, May 9-10, 2003 May, 2003
276. Effect of charge density on the electrophoretic mobility of acylated polyamidoamine dendrimers investigated by capillary electrophoresis. University of Michigan Medical School, Ann Arbor MI, Research Symposium, May 9-10, 2003 May, 2003
277. Fluorescence measurement of solid tumors using two-photon laser excitation through optic fibers University of Michigan Medical School, Ann Arbor MI, Research Symposium, May 9-10, 2003 May, 2003
278. Vaccines and Biologic Threats. 6th Annual Allergy & Asthma Symposium, Medical College of Toledo, Toledo OH April, 2003
279. Bioterrorism. 61st Annual Allergy & Immunology Program, University of Minnesota, Minneapolis MN April, 2003
280. Furthering Public Health Security: Project Bioshield Congressional Testimony Discussion before U.S. House of Representatives Subcommittee on Health and Subcommittee on Emergency Preparedness and Response, Washington DC. March, 2003
281. Interaction of Dendritic Polymers with Lipid Bilayers, Relationship Between Molecular Architecture and Biologic Activity American Physical Society, Austin TX. March, 2003
282. Anthrax and Smallpox as Bioterror Weapons 60th Meeting of the American Academy of Allergy, Asthma & Immunology, Denver CO. March, 2003
283. Hypereosinophilic Syndromes, Immunological Disorders I. ACAAI Literature Review for the 2003 ABAI Examination, Chicago IL March, 2003
284. Nanomolecular Therapeutics & Imaging General Electric (GE) Global Research, Niskayuna New York. March, 2003
285. Two-photon fiber optical detection of tumor fluorescence The fourth PI’s meeting of the UIP, San Diego, March 2003. March, 2003
286. Genetic Engineering of Organisms and Antibiotic Resistance Vaccines and Biological Threats Seminar, 60th Meeting of the American Academy of Allergy, Asthma & Immunology, Denver CO. March, 2003
287. Autoimmunity in Type I Diabetes 60th Meeting of the American Academy of Allergy, Asthma & Immunology, Denver CO March, 2003
288. Nanomolecular Therapeutics Distinguished Scientist Lecture Series, Bouve College of Health, Northeastern University, Boston MA February, 2003
289. Nanotechnology for Biological and Medical Applications. Nanotechnology, Biotechnology, Information Technology and Cognitive Science (NBIC) Convergence 2004, New York NY. February, 2003
290. Covering Permanent War and Bioterrorism: the Press and Public Policy Panel Discussion, University of Michigan Knight-Wallace Fellows, Ann Arbor MI January, 2003
291. Effect of polyamidoamine (PAMAM) dendrimers on membrane integrity: model and cell membranes 27th Macro Annual Symposium, Ann Arbor MI, 2003 January, 2003
292. Interaction of acetamide and amine terminated PAMAM dendrimers with lipid bilayer and cell membrane. CBTP Symposium, Ann Arbor MI, 2003 January, 2003
293. Engineered nanoparticles: fluorescent nanomaterials could let doctors monitor drug activity in cancer cells. Abstract, SPIE-The International Society for Optical Engineering, January, 2003. January, 2003
294. Enhanced biosensing using photonic crystal fibers Paper CMG2, presented at CLEO, Baltimore, 2003. January, 2003
295. Targeted drug delivery using multifunctional synthetic dendrimer nanodevice American Association of Cancer Research, Cancer Research 44: Abstract # 3671, Washington DC, 2003 January, 2003
296. Targeted drug delivery using multifunctional synthetic dendrimer nanodevice Abstract #3671, Cancer Research 44, American Association of Cancer Research, Washington DC 2003 January, 2003
297. Polyamidoamine (PAMAM) dendrimer interactions with model and cell membranes Membrane Biophysics Symposium at Michigan, Ann Arbor MI, 2003 January, 2003
298. Nanomolecular Therapeutics Pathology Grand Rounds, Yale University, New Haven CT January, 2003
299. Nanomolecular Therapeutics National Science Foundation/European Commission Workshop: From Nanomaterials to Nanotechnology, Boston MA December, 2002
300. Analysis of Poly(amidoamine) Dendrimers by Capillary Electrophoresis Macromolecular Science and Engineering 26th Annual Symposium, Ann Arbor MI October, 2002
301. Fas signaling in human thyroid epithelial cells Poster discussion, 74th Annual American Thyroid Association Meeting, San Francisco CA, October 2002 October, 2002
302. An approach to therapy for anaplastic carcinoma of the thyroid. Poster discussion, 74th Annual American Thyroid Association Meeting, San Francisco CA, October 2002 October, 2002
303. Antibody-dendrimer Conjugates for Targeted Prostate Cancer Therapy Polymer Material Science Engineering, Fall 2002 National ACS Annual PMSE Meeting October, 2002
304. Thyroid Autoimmunity: Association with other Autoimmune Diseases 74th Annual Meeting of the American Thyroid Association, Millennium Biltmore Hotel, Los Angeles CA. October, 2002
305. Nanomolecular Biosensors Oncological Nanotechnology Plenary Session, BioMems & Biomedical Nanotech World 2002 Meeting, Columbus OH September, 2002
306. Enabling concepts and materials for future biomedical sensor technology Panel Member, NIH Bioengineering Consortium Symposium, Bethesda MD, June 2002 June, 2002
307. Nanotechnology: Driving Advances in Medicine Matrix: Midland Festival (Dow), Midland MI April, 2002
308. Development of a Multifunctional Nanodevice Therapeutic Platform for the Treatment of Cancer 2nd International Meeting on Nanoparticles, Particles 2002, Orlando FL April, 2002
309. Bioterrorism: Relevance to Allergy and Immunology in Clinical Practice Medical Grand Rounds, Beaumont Hospital, Royal Oak MI. April, 2002
310. Nanotechnology: Biomedical and Therapeutic Applications AAPS-NE Regional Discussion Group, Rocky Hill CT. April, 2002
311. Bioterrorism: Threat and Immune Response Update in Allergy, Asthma & Immunology, Texas Technical University, Lubbock TX April, 2002
312. Autoimmunity in Type I Diabetes 58th Meeting of the American Academy of Allergy, Asthma & Immunology. March, 2002
313. Anthrax and Other Delights Michigan Journalism Fellows, Ann Arbor MI January, 2002
314. Entrepreneurial Faculty: Difficulties Encountered in Starting a Company From Bench to Bedside: Opportunities & Pitfalls in Technology Transfer, Wiesner Symposium, University of Michigan School of Business, Life Science Program December, 2001
315. The Decontamination of Anthrax Congressional Testimony before the U. S. House of Representatives, Science Committee November, 2001
316. Molecular Engineering in Nanotechnology IV: Computer Simulation and Visualization of a Multifunctional Device 9th Foresight Conference on Molecular Nanotechnology, Santa Clara CA. November, 2001
317. Molecular Engineering in Nanotechnology II: Structure and Composition of Multifunctional Devices for Medical Application 9th Foresight Conference on Molecular Nanotechnology, Santa Clara CA November, 2001
318. Molecular Engineering in Nanotechnology I: Multifunctional Device for Biomedical Application 9th Foresight Conference on Molecular Nanotechnology, Santa Clara CA. November, 2001
319. Bioterrorism. Panel Discussion on Terrorism, Ann Arbor Economic Development Club, Ann Arbor MI. November, 2001
320. Cytokines and their Influence on Thyroid Function Meet the Professor Supper, 74th Annual Meeting of the American Thyroid Association, Washington DC. November, 2001
321. Molecular Engineering in Nanotechnology IV: Atomic Force Microscopy Characterization of Dendrimer Drug-delivery Agents 9th Foresight Conference on Molecular Nanotechnology, Santa Clara CA November, 2001
322. Anthrax as a Bio-Threat Presentation for the Michigan Congressional Delegation, Washington DC October, 2001
323. Decontamination of the Brentwood Post Office United States Postal Service, Washington DC. October, 2001
324. Nanoemulsions Antimicrobials and Vaccines ATACCC01, Ft. Walton Beach FL September, 2001
325. Nanomolecular Therapeutics C.B. Reactions in Organized Assemblies, Gordon Research Conference, New London CT July, 2001
326. Imaging and Drug Delivery with Dendrimer Nanocomposites Invited lecture, 1st International Meeting on Nanoparticles, Chicago IL June, 2001
327. Decontamination of B Anthracis Simulant from Typical Office Environment Surfaces Using a Novel Nanoemulsion. ASM Spring Meeting, Orlando Florida May, 2001
328. Antimicrobial NanoEmulsions Useful for Decontamination of Food Processing Plants ASM Spring Meeting, Orlando FL May, 2001
329. Apoptosis in Thyroiditis Endocrine Grand Rounds, Mayo Clinic, Rochester. May, 2001
330. Nanostructures Unique Applications International Biotech & Infotech Summit, San Francisco CA. May, 2001
331. Inhibition of Influenza A Agglutination and Infection Using Sialic-acid Conjugated PAMAM Dendrimer; HIA and a Murine Model Study ASM Spring Meeting, Orlando Florida May, 2001
332. Antimicrobial Therapeutics for Anthrax American Chemical Society National Meeting, San Diego CA. April, 2001
333. Imaging of Gold Dendrimer Nanocomposites in Cells. Symposium Y, Synthesis, Functional Properties and Applications of Nanostructures MRS Spring Meeting, San Francisco CA. April, 2001
334. Autoimmune/Immunologically-Mediated Diseases of Eyes, Endocrine Glands, Kidney, Reproductive Organs, Nervous System; Vasculitis; Anti-Inflammatory Drugs; Antibody-Dependent Cell-Mediated Immunity, Immune Complexes and Immune Complex Disease. American College of Allergy, Asthma & Immunology, Conjoint Committee/Board ABAI Literature Review, Chicago IL. April, 2001
335. Fas, Cell Death and Its Role in Autoimmunity Advanced Research-Lunch Seminar, 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, New Orleans LA. March, 2001
336. Nanomedicine: Playing on the Size Scale of Biology Itself. Association of American Medical Colleges Council of Academic Societies, San Antonio TX March, 2001
337. Dendrimer-Based Nanosensors to Target Cells In Vivo and Delivery Therapeutics. NanoSpace 2001: Exploring Interdisciplinary Frontiers, Galveston TX March, 2001
338. Nanomaterial Applications for Pathogen Defense. Scientific Conference on Chemical & Biological Defense Research, Hunt Valley MD March, 2001
339. Biomedical Science and the Response to Potential Biologic Weapons Workshop on Unified Science & Technology for Biological Threat Reduction” sponsored by The Center for Advanced Studies-University of New Mexico & Sandia National Laboratories-Center for National Security & Arms Control, Albuquerque NM March, 2001
340. Imaging and Drug Delivery Using Dendrimer Nanocomposites 1st International Meeting on Nanoparticles, Orlando FL. February, 2001
341. Nanotechnology in Early Detection and Prevention of Cancer Workshop NCI/National Institute of Standards and Technology, Gaithersburg MD January, 2001
342. Nanoemulsion Therapeutics Drug Discovery World, Cambridge Biotechnology Conference, Boston MA January, 2001
343. Nanotechnology: Small Solutions for Big Problems 20th Annual Meeting of the Society for Physical Regulation in Biology and Medicine, Charlotte SC. January, 2001
344. Biologic Applications of Nanomaterials George Washington University Grand Rounds, Washington DC January, 2001
345. Dendrimer-Based Nanosensors to Sense and Report Bio-Signatures and Events from Living Cells. Nanotechnology for Biodetection/Bioassay and Delivery of Therapeutics to Individual Cells Workshop, Scottsdale AZ December, 2000
346. Nanomolecular Therapeutics. Emerging Technologies Seminar, University of Texas-Southwestern, Dallas TX. December, 2000
347. Structural Characterization of An Amine-terminated Hybrid Dendrimer: Molecular Dynamics Studies. 8th Foresight Conference on Molecular Nanotechnology, Bethesda MD November, 2000
348. Synthesis and Characterization of Novel POPAM-PAMAM (POMAM) Hybrid Dendrimers as Reactive Modules for Nanodevice Construction 8th Foresight Conference on Molecular Nanotechnology. November, 2000
349. Thyroid Autoimmunity 12th International Thyroid Congress, Kyoto Japan October, 2000
350. Inflammatory Cytokines Enhance Apoptosis and Transforms Non-destructive to Destructive Thyroiditis in Murine Experimental Autoimmune Thyroiditis 12th International Thyroid Congress, Kyoto Japan. October, 2000
351. Bio-molecular systems and technology NASA/NCI Collaborative Working Group Meeting, Washington DC, April 2000 April, 2000
352. Fas, Cell Death and Its Role in Autoimmunity Advanced Research Seminar, American Academy of Allergy, Asthma and Immunology March, 2000
353. Moderator, Autoimmunity Poster Discussion Group. American Thyroid Association 72nd Annual Meeting, Palm Beach FL, October 1999. October, 1999
354. Induction of Bcl-2 Expression in Thyrocytes by 1(alpha), 25-dihydroxyvitamin D3 is Associated With Activation of the Protein kinase C Pathway American Thyroid Association 72nd Annual Meeting, Palm Beach FL. October, 1999
355. Trail Expression and Function in Thyroid Follicular Cells American Thyroid Association 72nd Annual Meeting, Palm Beach FL. October, 1999
356. Exploring biotechnology Experts Overview Panel, Office of Net Assessment, Office of the Secretary of Defense, McLean VA, October 1999 October, 1999
357. Inflammatory Cytokine Regulation of Fas-mediated Apoptosis in Thyroid Follicular Cells Endocrine Society’s 81st Annual Meeting, San Diego CA June, 1999
358. Enhancing the Bactericidal Activity of Surfactant Lipid Preparation ASM Meeting, Chicago IL. May, 1999
359. Inhibitory Effect of a Novel Surfactant Lipid Preparation (BCTP 401) on the Infectivity of Enveloped Viruses ASM Meeting, Chicago IL May, 1999
360. PAMAM Dendrimer Inhibition of Influenza A Virus Adsorption and Infection as a Function of Generation and Molar Ratio of Receptor Conjugation ASM Meeting, Chicago IL. May, 1999
361. Fungicidal Effect of a “Hybrid” Surfactant Lipid Preparation (SLP) on Candida SPP. ASM Meeting, Chicago IL. May, 1999
362. Sporicidal Effect of Novel Surfactant Lipid on Bacillus Cereus. ASM Meeting, Chicago IL. May, 1999
363. Bactericidal mechanisms of surfactant lipid preparations ASM Meeting, Chicago IL. May, 1999
364. Intravascular and Endobronchial Gene Transfer in Mouse Lung in vivo Experimental Biology 1999 Meeting, Washington DC April, 1999
365. Topical Gene Transfer To the Skin using Collagen Membrane-based Dendrimer/DNA Complexes Experimental Biology 1999 Meeting, Washington DC. April, 1999
366. Regulation of Fas-mediated Apoptosis in Thyroid Follicular Cells 26th Meeting of the European Thyroid Association, Milan Italy January, 1999
367. Effects of a Non-ionic Surfactant on Polymer Mediated Transfection AAPS National Meeting, San Francisco CA November, 1998
368. Inactivation of Bacillus Anthracis Spores by a Nontoxic Surfactant a Nanoemulsion 38th ICAAC Meeting, San Diego CA. September, 1998
369. Inhibitory Effect of Non-phospholipid Liposomes and Nanoemulsions on Influenza A Virus Infectivity 38th ICAAC Meeting, San Diego CA. September, 1998
370. TNF-related Apoptosis Inducing Ligand (TRAIL) Induces Programmed Cell Death in Thyrocytes. The American Thyroid Association, Portland OR September, 1998
371. The Induction of Apoptosis in Thyroid Cells by Ultraviolet Irradiation (UV) is Prevented by 1a,25 -dihydroxyvitamin D3 The American Thyroid Association, Portland OR September, 1998
372. Up-regulation of Fas Expression on Thyroids with Papillary Carcinoma The American Thyroid Association, Portland OR September, 1998
373. Fap-1 is Present in Human Thyroid Follicular Cells and Functions As An Inhibitor of Fas-mediated Signaling of Programmed Cell Death Annual Meeting, The American Thyroid Association, Portland OR. September, 1998
374. revention of influenza A virus infection through virus inactivation by nanoemulsions of non-phospholipid liposomes. Abst. M-75, 38th ICAAC Meeting, San Diego CA, September 1998 September, 1998
375. 1a,25-dihydroxyvital D3 Up-regulates Bcl-2 Expression and Induces Protection From the Induction of Programmed Cell Death in Normal Thyrocytes Annual Meeting, The Endocrine Society, New Orleans LA. June, 1998
376. Biocidal Effect of Unique Lipid Surfactants on Bacillus Spores Annual Meeting American Society for Microbiology, Atlanta GA May, 1998
377. Sialic acid conjugated dendritic polymers inhibit influenza virus binding to target cells in a structural and virus strain-specific manner Abst. A-77. Annual Meeting, American Society for Microbiology, Atlanta GA, May 1998 May, 1998
378. Microbicidal Effects of Liposome-like Microemulsions on Pathogenic Gram Negative Bacteria Annual Meeting American Society for Microbiology, Atlanta GA. May, 1998
379. The Effect of Phophodiester Oligonucleotides on Mediator Release From Mast Cells. Annual Meeting, American Association of Allergy Asthma and Immunology, Washington DC March, 1998
380. An Examination of Fas Ligand Expression on Thyrocytes. The American Thyroid Association, Colorado Springs CO. October, 1997
381. Induction of Apoptosis Through the Fas Death Pathway is Blocked by a Llabile Inhibitor in Thyrocytes The American Thyroid Association, Colorado Springs CO. October, 1997
382. IL-1ß Induction of the BCL-2 Gene Family Member BFL-1 is Associated With Protection Against Cell Death in Thyrocytes The American Thyroid Association, Colorado Springs CO October, 1997
383. Surfactant Provides a Major Barrier to Non-viral Gene Transfer in the Endobronchial Tree Department of Pathology, University of Michigan, Ann Arbor MI. June, 1997
384. The Use of Autoantibodies in the Diagnosis of Autoimmune Thyroid Disease The Endocrine Society, Minneapolis MN. June, 1997
385. TSH Blocks the Induction of Apoptosis in Thyroid Follicular Cells But Does Not Alert the Expression of Fas (APO-1, CD95). American Association of Allergy Asthma and Immunology, San Francisco CA. February, 1997
386. Fas (APO-1, CD95) is Expressed on Thyroid Follicular Cells; However the Engagement of Fas on These Cells Does Not Consistently Lead to the Induction of Apoptosis. The American Thyroid Association, San Diego CA. November, 1996
387. Kidney Transplantation from a Blood Group A2 Donor to a Group O Recipient with a 7 HLA Antigen Match 22nd Annual Meeting, American Society for Histocompatibility and Immunogenetics, San Diego CA October, 1996
388. Cells Specific Transfer of Genetic Material into Eukaryotic Cells using Synthetic Polymer Joint Meeting, ASBMB, ASIP, AAI, New Orleans LA June, 1996
389. Modulation of Gene Expression by Antisense Oligonucleotides and Expression Plasmids Transfected with Starburst PAMAM Dendrimers Joint Meeting, ASBMB, ASIP, AAI, New Orleans LA. June, 1996
390. Efficient Transfer and Expression of Genetic Material in vivo in Rat Lung using Starburst Dendrimer Synthetic Vectors Annual Meeting American Academy of Allergy, Asthma, and Immunology, New Orleans LA. March, 1996
391. Mid and High Resolution Typing Obtained Through a Single Polymerase Chain Reaction 22nd Annual Meeting, American Society for Histocompatibility and Immunogenetics, San Diego CA. February, 1996
392. Thyroid peroxidase is an autoantigen in non-obese diabetic mice with thyroiditis. Poster symposium, The American Thyroid Association, 11th International Thyroid Congress, Toronto Canada, Sep 1995. September, 1995
393. Expression of Chemokines, Cytokines and Adhesion Molecules in Late-phase Allergic (LAR) Lung Inflammation in Rats Passively Sensitized with Monoclonal IgE Antibody. American Thoracic Society, AAA/ATS Conference on Asthma July, 1995
394. Proliferation of splenic mononuclear cells from NOD mice in response to staphylococcal superantigens Poster presentation, 9th International Congress of Immunology, San Francisc CA, July 1995 July, 1995
395. The Efficient Development of Cells Persistently Expressing Transferred Genetic Material using Starburst Dendrimers Clinical Research, San Diego CA May, 1995
396. Efficient Transfer and Expression of Genetic Material in Eukaryotic Cells using Starburst Dendrimer Conjugates Experimental Biology, Atlanta GA April, 1995
397. Unique characteristics of Starburst dendrimers in in vitro DNA transfer Poster presentation, Experimental Biology, Atlanta GA, Apr 1995 April, 1995
398. Histamine release does not relate to the development of the late allergic response (LAR) in rats passively sensitized with IgE Poster presentation, The American Academy of Allergy and Immunology, New York City NY, Feb 1995 February, 1995
399. Upregulation of chemokines, cytokines and adhesion molecules in a rat model of late-phase allergic lung inflammation Poster presentation, The American Academy of Allergy and Immunology, New York City NY, Feb 1995. February, 1995
400. Characteristics of the immune response to thyroid peroxidase in patients with post-partum thyroiditis, poster Poster presentation, The American Thyroid Association, Chicago IL, Sep 1994. September, 1994
401. Permanent reversal of diabetes but not thyroiditis in NOD mice treated with Bacillus Calmette-Guerin (BCG) or bacterial superantigens Poster presentation, Clinical Research Meeting, Baltimore MD, Apr 1994. April, 1994
402. The induction of thyroid peroxidase (TPO) immune responses in patients with thyroid cancer (TC). Poster presentation, American Association for Cancer Research, San Francisco CA, Apr 1994 April, 1994
403. The induction of cutaneous and pulmonary delayed-phase allergic inflammation in an in vivo rat model. Poster presentation, Clinical Research Meeting, Baltimore MD, Apr 1994. April, 1994
404. The induction of thyroid peroxidase (TPO) immune responses in patients with thyroid cancer (TC). Poster presentation, American Academy of Allergy & Immunology Annual Meeting, Anaheim CA, Mar 1994. March, 1994
405. Variables altering cutaneous and pulmonary infiltrates in an in vivo model of delayed-phase allergic inflammation. Poster presentation, American Academy of Allergy & Immunology Annual Meeting, Anaheim CA, Mar 1994 March, 1994
406. Identification of Localized Autoantibody Epitopes in the Amino Acid 513-633 (TPO 513-633) Region of Thyroid Peroxidase (TPO). American Thyroid Association 67th Annual Meeting, Tampa FL. November, 1993
407. Native thyroid peroxidase is a disulfide-linked dime Poster presentation, American Thyroid Association 67th Annual Meeting, Tampa FL, Nov 1993 November, 1993
408. Differential effect of immunization with bacillus calmette-guerin (BCG) on the incidence of diabetes mellitus (DM) and thyroiditis in non-obese diabetic (NOD) mice Poster presentation, Endocrine Society Annual Meeting, Las Vegas NV, Jun 1993. June, 1993
409. An in vivo model of pulmonary delayed-phase allergic inflammation Poster presentation, AAI/CIS Meeting, Denver CO, May 1993. May, 1993
410. T Cell Mediated Anti-tumor Immunity AAI/CIS Meeting, Denver CO May, 1993
411. Identification of a Localized Autoantibody Epitope in Thyroid Peroxidase (TPO) that is Associated with Hashimoto's Disease American Federation of Clinical Research Meeting, Washington DC. April, 1993
412. Identification of a Localized Autoantibody Epitope in Thyroid Peroxidase (TPO) that is Associated with Hashimoto's Ddisease NIDDK and ORWH Workshop on Autoimmune Thyroid Disease, Bethesda MD. April, 1993
413. Tissue Specificity and Serologic Reactivity of an Autoantigen Associated with Autoimmune Thyroid Disease American Thyroid Association Annual Meeting, Rochester MN. September, 1992
414. The Identification of Two Areas of Human Auto-antibody Binding in Thyroid Peroxidase Endocrine Society Annual Meeting, San Antonio TX. June, 1992
415. The Induction of Heat Shock Protein 70 (HSP 70) on Human Thyroid Cells and Fisher Rat tThyroid (FRTL-5) Cells. AAP/ASCI/AFCR Annual Meeting, Baltimore MD. May, 1992
416. Epitope Specificity of Thyroid Peroxidase (TPO) Autoantibodies in Common-variable Hypogammaglobulinemia (CVH) Patients with Hashimoto's Thyroiditis (HT). Annual Meeting of the American Academy of Allergy and Immunology, Orlando FL March, 1992
417. Localization of an Epitope in Thyroid Peroxidase (TPO) Recognized by Hashimoto's Patients (HP) Autoantibodies. Annual Meeting of the Endocrine Society, Washington DC. June, 1991
418. Identification of Thyroid histones as auto-antigens using human monoclonal antibodies. National Meeting of the American Federation of Clinical Research, Washington DC. May, 1989
419. Evaluation of the binding characteristics of human monoclonal antibodies directed against histones Poster presentation, National Meeting of the American Federation of Clinical Research, Washington DC, May 1989. Clin Res 37:588A, 1989 May, 1989
420. Rapid diagnosis of cytomegalovirus infection in immunocompromised individuals using enzyme-labeled in-situ hybridization. Poster presentation, National Meeting of the American Academy of Allergy and Immunology, San Antonio TX, March 1989 March, 1989
421. Unusual Cytoplasmic Nucleoproteins are Autoantigens in Graves' Disease (GD). Central Society for Clinical Investigation January, 1989
422. Flow Cytometric Quantitation of HIV-antigen Positive Lymphocytes in Individuals Infected with HIV IV International Conference on AIDS, Stockholm Sweden. June, 1988
423. A Single Human Monoclonal Antibody with Activity of TSI, TBII and TGSI. National Meeting of the American Federation of Clinical Research, Washington DC. May, 1988
424. Flow Cytometric Quantitation of HIV-antigen Positive Lymphocytes in Individuals Infected with HIV. National Meeting of the American Academy of Allergy and Immunology, Anaheim CA March, 1988
425. Urinary abnormalities in patients infected with human immunodeficiency virus. Poster presentation, Regional Meeting of the American College of Physicians, San Francisco CA, Oct 1987 October, 1987
426. Immunoglobulin and T cell Gene Rearrangements Demonstrate that the Immune Response in Autoimmune Thyroid Disease (AITD) is Polyclonal in Nature Annual Meeting of the American Thyroid Association National Meeting, Washington DC September, 1987
427. Improved graft survival and decreased incidence of rejection in black cadaveric renal recipients receiving CsA, steroids and prophylactiv ALG. Poster presentation, International Organ Transplant Forum, Pittsburgh PA, Sep 1987. September, 1987
428. Thyroid Autoantigen Heterogeneity Demonstrated by Immunoblotting European Medical Research Society Meeting. June, 1987
429. Natural Killer Cell Activity in Postpartum Women Annual Meeting of the Endocrine Society, Indianapolis IN. June, 1987
430. Human Monoclonal Antibody with Thyroid Stimulating Activity Annual Meeting of the Endocrine Society, Indianapolis IN. June, 1987
431. Isolation of the Immune Response in Hashimoto's Disease to Intrathyroidal Lymphocytes and the Production of Human Monoclonal Antibodies Annual Meeting of the American Thyroid Association, Phoenix AZ. September, 1986
432. Development of an Antigen-responsive Intrathyroidal T Cell Population: Evidence that Thyrocyte Antigens and OKT3 T Cell Receptor Mediate Cellular Proliferation Annual Meeting of the American Thyroid Association, Phoenix AZ September, 1986
433. Thyroid-stimulating and Thyrotropin Binding-inhibiting Immunoglobulins in Patients with Systemic Lupus Erythematosus (SLE). First IUIS Conference on Clinical Immunology, 6th International Congress of Immunology, Toronto Canada July, 1986
434. Intrinsic Abnormality of Thyroid Cells from a Brobdingnagian Goiter The Annual Meeting of the Endocrine Society, Anaheim CA June, 1986
435. Human Monoclonal Antibodies Derived from Peripheral Blood Lymphocytes of Graves' Disease Patients which Inhibit both TSH and Graves' IgG-mediated Production of cAMP American Federation for Clinical Research National Meeting, Washington DC May, 1986
436. Serum Immunoglobulins in Patients with Graves' Ophthalmopathy Directed Against Unique Determinants of Porcine Eye Muscle American Federation for Clinical Research National Meeting, Washington DC. May, 1986
437. Mouse Monoclonal Aantibodies to Hhuman Thyrocyte Membrane Proteins which Augment both TSH and Graves' IgG Mediated Production of cAMP American Federation for Clinical Research National Meeting, Washington DC. May, 1986
438. Pharmacodynamics of Theophylline in Patients on Chronic Therapy American Academy of Allergy/Immunology, New Orleans LA. March, 1986
439. A Clinically-relevant ELISA for Human Thyroglobulin American Academy of Allergy and Immunology, Washington DC. February, 1986
440. The Use of In-line Infusion Filters Relieves Adverse Reactions to IV IgG American Academy of Allergy and Immunology, Washington DC February, 1986
441. The Role of Antibody Dependent Cytotoxicity and Natural Killer Cells in Hashimoto's Disease. International Thyroid Meeting, Sao Paulo Brazil September, 1985
442. Natural Killer Cells in Hashimoto's Thyroiditis Annual Meeting of the Endocrine Society, Baltimore MD June, 1985
443. Natural killer cells in hashimoto's thyroiditis Endocrine Society Program, Abstract 724, Jun 1985. June, 1985
444. Anti-heart Antibodies in Inflammatory Cardiomyopathy Military Cardiology Society, EL Paso TX. June, 1985
445. Influence of HLA-DR and Racial Match on Graft Survival in Blacks Receiving Cyclosporine D. Bernard Amos Symposium in Transplantation Immunology, Durham NC May, 1985
446. Anti-TSH Receptor Antibody and Anti-idiotypic Antibody Containing Immune Complexes in Graves' Disease American Federation of Clinical Research National Meeting. May, 1985
447. Comparison of Four Sustained-release Theohylline Preparations Annual Meeting of the American Academy of Allergy and Immunology, New York NY March, 1985
448. Beta-adrenergic Ligand Binding Antibodies (BLA) in Adult, Steroid Dependent Asthmatics Annual Meeting of the American Academy of Allergy and Immunology, New York NY March, 1985
449. IgE Containing Immune Complexes in Urticarial Disorders. Annual Meeting of the American College of Allergy, Miami FL. February, 1985
450. Characterization of a Monoclonal Antibody Developed Against the TSH Receptor Annual Meeting of the American Thyroid Association, New York NY September, 1984
451. Anti-TSH Antibodies in the Sera of Graves' Patients which Display Anti-idiotypic Activity Against TSH Receptor Purified Graves' IgG. Annual Meeting of the American Thyroid Association, New York NY. September, 1984
452. Production, Isolation and Characterization of Anti-idiotypic Antibodies Directed Against Human Anti-TSH Receptor Antibodies American Federation of Clinical Research National Meeting, Washington DC. May, 1984
453. Functional Characterization of Anti-thyrotropin Antibodies in the Sera of Graves' Patients. American College of Physicians Annual Meeting, Atlanta GA April, 1984
454. Immediate Hypersensitivity Skin Testing in Uremia American College of Allergists Annual Meeting, San Francisco CA. April, 1984
455. Use of Immunoblotting Techniques for IgE Determination American College of Allergists Annual Meeting, San Francisco CA April, 1984
456. The Development of Monoclonal Antibodies Directed Against Putative Anti-TSH Receptor Antibodies Satellite Symposium of Auto Immunity and the Thyroid. January, 1984
457. Preparation of Biotinylated Receptor Purified Graves' IgG: A Simple Technique Allowing Direct Functional Assessment of TSH Receptor Antibody Interaction with Membranes Satellite Symposium of Auto Immunity and the Thyroid January, 1984
458. Circulating Beta Ligand Antibodies in Auto-immune Thyroid Disease Annual Meeting of the American Thyroid Association, New Orleans LA. September, 1983
459. Class of Antibodies Binding the Thyroid Stimulating Hormone Receptor in Active Graves’ Disease. Annual Meeting of the American Thyroid Association, New Orleans LA. September, 1983
460. Reliability of Bayesian Pharmacokinetic Forecasting to Achieve Target Blood Levels for Research Purposes II World Conference on Clinical Pharmacology and Therapeutics, Washington DC July, 1983
461. A Sensitive and Rapid Enzyme-linked Immunosorbent Assays (ELISA) for Thyroid Stimulating Hormone receptor Antibodies American Federation for Clinical Research National Meeting. April, 1983
462. Computer-assisted Pharmacokinetic Evidence that Theophylline Induced Brochodilatory Response Varies With But Lags Behind Fluctuations in Serum Theophylline Levels in the Therapeutic Range. American Academy of Allergy Meeting in Miami FL. March, 1983
463. Targeted drug delivery to tumor-expressing folate receptor using dendrimer-based therapeutic nanodevice in vivo. NA March, 1983
464. Theophylline pharmacodynamics: counter-clockwise hysteresis and its clinical implication Abstract, II World Conference on Clinical Pharmacology and Therapeutics, Washington DC, 31 Jul - Aug 1983 January, 1983



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Miami 2012 Winter Symposium: Nanotechnology in Biomedicine Miami 2012 Winter Symposium: Nanotechnology in Biomedicine February, 2012

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.